India Pharma Outlook Team | Friday, 06 March 2026
Novo Nordisk’s blockbuster diabetes and weight-loss drug is at the center of a massive shake-up in India’s pharmaceutical market.
As the patent for semaglutide—the key ingredient behind globally popular injections like Ozempic and Wegovy—nears expiry in India, more than 50 new brands are preparing to enter the market, triggering what industry insiders are calling a “Sema storm.”
The rush comes as the semaglutide patent expiry in India is expected around March 2026, opening the door for domestic pharmaceutical companies to manufacture and sell generic versions of the drug for the first time. The development is likely to transform the country’s diabetes and weight-loss treatment market while dramatically lowering prices for patients.
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which help regulate blood sugar and reduce appetite. Originally designed to treat type-2 diabetes, the drug quickly gained global popularity after clinical results showed significant weight-loss benefits. The injectable therapy works by slowing digestion and making people feel full for longer, helping control calorie intake.
Also Read: Advancing Interventional Radiology in India Through Collaboration
With patent protection ending, Indian pharmaceutical companies have moved quickly to claim their share of the market. Several major drugmakers—including Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Natco Pharma—are preparing generic versions of semaglutide. Some companies are planning to launch their products immediately after the patent expiry window.
Neeraj Sharma, MD & CEO, OneSource Specialty Pharma said, “The semaglutide launch is not just another product in our pipeline; it is a strategic imperative that will redefine our growth trajectory for the next five years.”
Industry reports suggest dozens of brand names have already been filed, many starting with the prefix “Sema.” The lineup includes names such as Semaglip, Sematop, Semakind, Semastrike and Semaril, highlighting how crowded the market could become once generics are approved. The surge of registrations reflects the massive commercial opportunity attached to the molecule.
Demand for weight-loss medications has surged worldwide, especially after celebrity endorsements and viral social media trends. India, often described as the diabetes capital of the world, presents a huge market for drugs that help manage blood sugar and obesity. As a result, companies are racing to build early market share once the semaglutide patent expiry removes the legal barriers for generics.
Experts believe the arrival of low-cost versions could significantly expand access to treatment. Currently, imported versions of Ozempic and similar drugs are expensive and out of reach for many patients. With Indian manufacturers entering the market, prices are expected to drop sharply, making the drug more accessible for diabetes management and medically supervised weight loss.
However, doctors are also warning about the risks of misuse. The growing popularity of the drug for cosmetic weight loss has raised concerns among healthcare professionals. Medical experts stress that semaglutide is a prescription medicine meant for specific metabolic conditions and should not be used without proper medical supervision.
Sharvil Patel, Managing Director, Zydus Lifesciences said, “We are preparing for a day-one launch of semaglutide once the patent expires because we believe this therapy will significantly improve access for patients.”
The pharmaceutical race around semaglutide also reflects the broader shift in the global obesity-drug market. Indian manufacturers are known for producing affordable generics at scale, which could eventually reshape the availability and pricing of these therapies in many countries.
Key Data And Market Insights
As the patent clock runs out, the coming months could reshape the pharmaceutical landscape. For Indian drugmakers, the opportunity is enormous. For patients, the semaglutide patent expiry could finally bring a widely discussed treatment within financial reach.
